Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Double-blind, Randomized, Dose Finding Clinical Trial With an Open-label run-in Part to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years

NCT06334393 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT06334393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06334393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Double-blind, Randomized, Dose Finding Clinical Trial With an Open-label run-in Part to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years
Lead sponsor
Valneva Austria GmbH
Phase
Phase 1
Overall status
Completed
Start date
March 25, 2024
Completion date
February 27, 2026
Enrollment
150 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

zika, zika virus infection